Morgan Stanley lowered the firm’s price target on Inspire Medical (INSP) to $60 from $130 and keeps an Equal Weight rating on the shares. Following Q4 earnings, the firm makes a number of changes to its estimates through 2029, telling investors that the company’s recent cut to its FY26 sales guidance “raised new uncertainties that affect our thesis.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical price target lowered to $67 from $89 at UBS
- Inspire Medical downgraded to Peer Perform from Outperform at Wolfe Research
- Inspire Medical Weighs Growth Against Reimbursement Risks
- Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
- Inspire Medical price target lowered to $68 from $90 at RBC Capital